TFF PHARMACEUTICALS, INC. (TFFP): Price and Financial Metrics


-0.04 (-0.55%)

POWR Rating

Component Grades













Add TFFP to Watchlist
Sign Up

Industry: Biotech


of 465

in industry


  • Sentiment is the dimension where TFFP ranks best; there it ranks ahead of 75.31% of US stocks.
  • The strongest trend for TFFP is in Value, which has been heading down over the past 155 days.
  • TFFP's current lowest rank is in the Momentum metric (where it is better than 4.1% of US stocks).

TFFP Stock Summary

  • For TFFP, its debt to operating expenses ratio is greater than that reported by only 0.39% of US equities we're observing.
  • With a price/sales ratio of 2,581.65, TFF Pharmaceuticals Inc has a higher such ratio than 99.59% of stocks in our set.
  • As for revenue growth, note that TFFP's revenue has grown 213.24% over the past 12 months; that beats the revenue growth of 96.5% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TFF Pharmaceuticals Inc are SRRA, ASND, CRDF, LXRX, and CRMD.
  • TFFP's SEC filings can be seen here. And to visit TFF Pharmaceuticals Inc's official web site, go to

TFFP Valuation Summary

  • In comparison to the median Healthcare stock, TFFP's EV/EBIT ratio is 124.57% lower, now standing at -7.2.
  • Over the past 23 months, TFFP's price/sales ratio has gone NA NA.
  • Over the past 23 months, TFFP's price/earnings ratio has gone up 10.4.

Below are key valuation metrics over time for TFFP.

Stock Date P/S P/B P/E EV/EBIT
TFFP 2021-08-31 8411.5 3.9 -9.4 -7.2
TFFP 2021-08-30 8430.8 3.9 -9.4 -7.2
TFFP 2021-08-27 8342.3 3.9 -9.3 -7.1
TFFP 2021-08-26 7953.8 3.7 -8.9 -6.6
TFFP 2021-08-25 8107.7 3.8 -9.1 -6.8
TFFP 2021-08-24 8303.8 3.9 -9.3 -7.0

TFFP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TFFP has a Quality Grade of D, ranking ahead of 8.49% of graded US stocks.
  • TFFP's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TFFP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -13.217
2021-03-31 0.001 1 -26.319
2020-12-31 0.000 NA -46.985
2020-09-30 0.000 NA -310.219
2020-06-30 0.000 NA 41.705
2019-12-31 0.000 NA 70.796

TFFP Price Target

For more insight on analysts targets of TFFP, see our TFFP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.00 Average Broker Recommendation 1.5 (Moderate Buy)

TFFP Stock Price Chart Interactive Chart >

Price chart for TFFP

TFFP Price/Volume Stats

Current price $7.26 52-week high $21.14
Prev. close $7.30 52-week low $6.39
Day low $6.97 Volume 142,200
Day high $7.43 Avg. volume 196,080
50-day MA $7.82 Dividend yield N/A
200-day MA $8.97 Market Cap 184.20M


TFF Pharmaceuticals, Inc. operates as an early-stage biopharmaceutical company. The Company develops powder and molecule drugs for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals serves clients in the State of Texas.

TFFP Latest News Stream

Event/Time News Detail
Loading, please wait...

TFFP Latest Social Stream

Loading social stream, please wait...

View Full TFFP Social Stream

Latest TFFP News From Around the Web

Below are the latest news stories about TFF Pharmaceuticals Inc that investors may wish to consider to help them evaluate TFFP as an investment opportunity.

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP): Are Analysts Optimistic?

We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the...

Yahoo | January 12, 2022

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic

Yahoo | December 21, 2021

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30p

Yahoo | December 6, 2021

TFF Pharmaceuticals (NASDAQ:TFFP) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of TFF Pharmaceuticals (NASDAQ:TFFP) from a hold rating to a sell rating in a research report report published on Friday, reports. According to Zacks, TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory []

Transcript Daily | November 20, 2021

TFF Pharmaceuticals, Inc. (TFFP) Q3 2021 Earnings Call Transcript

With me on the line today is Glenn Mattes, president and CEO of TFF and Kirk Coleman, chief financial officer; Dr. Dale Christensen, TFF director of clinical development; and Dr. The press release announcing our third quarter results is available on the TFF Pharmaceuticals website.

Yahoo | November 16, 2021

Read More 'TFFP' Stories Here

TFFP Price Returns

1-mo -11.25%
3-mo -7.52%
6-mo -22.52%
1-year N/A
3-year N/A
5-year N/A
YTD -18.15%
2021 -38.06%
2020 167.66%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7447 seconds.